–Document will inform development of report for public deliberation by the Midwest CEPAC–

August 1, 2016 – The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document that will inform a report on drug therapies for rheumatoid arthritis. The document will be open to public comment for three weeks.

The draft scoping document was developed with input from a number of patient groups, clinical experts, and other stakeholders. In addition, stakeholders were invited to submit any information relevant to the review during a three-week long open input period that began with the announcement of the topic. While an initial announcement of the topic indicated that ICER may consider treatments for psoriatic arthritis alongside those for rheumatoid arthritis, feedback received from patient groups, manufacturers, and other stakeholders strongly indicated that the two disease areas have such important differences in patient-centered outcomes that they should be considered separately. ICER will focus only on rheumatoid arthritis for this review and will consider reviewing treatments for psoriatic arthritis as a future topic.

The scoping document will guide development of a report that will serve as the basis for deliberation and discussion at an upcoming public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) to be held on January 26, 2017. The Midwest CEPAC is a core program of ICER.

Continue reading at ICER-review.org